skip-to-main-content
Donate
Why give?

 Industry symposia


The following symposia are supported by the indicated patrons and are available free to delegates to attend. 

Symposia details will be updated as they become available.

These sessions are not certified by University of Toronto, the College of Family Physicians of Canada or the Royal College of Physicians and Surgeons of Canada, nor are they under the jurisdiction of the Heart & Stroke Clinical Update.

Friday December 8, 2017 

7:00

Randomized Control Trials and Real World Evidence: Where do they fit? 

Breakfast symposium supported by AstraZeneca Canada Inc.

Peter Lin, MD CCFP

Learning objectives: 

  • Evaluate and understand the differences between randomized clinical trials and real world evidence. 
  • Understand what information and learnings can be derived from each.
  • Review real world evidence examples and how they may apply to practice.

Cardiovascular outcomes trials are becoming a key component of determining the safety and efficacy of type 2 diabetes management therapies. This program is designed to review the clinical trial landscape understanding and evaluating both randomized control trials and real world evidence. You will gain a deeper understanding of how to compare and contrast the different trials as well as review some examples and apply to everyday practice.

12:50

Choosing the Best Option for Patients: Integrating GLP-1RAs into Type 2 Diabetes Management

Lunch symposium supported by Novo Nordisk Canada Inc.

Robert Schlosser, MD, FRCPC
Endocrinologist at LMC Endocrinology Centre, Thornhill, Ont.

Learning objectives:

  • Assess the role of GLP-1 receptor agonist (GLP-1RA) therapy in T2DM, focusing on recommendations from Diabetes Canada.
  • Compare and contrast the efficacy, safety and dosing of current and upcoming GLP-1RAs.
  • Discuss how to integrate the GLP-1RA class into practice, reflecting on specific patient and agent characteristics to optimize T2DM management.

Diabetes Canada recommends that Canadian healthcare providers select a pharmacologic treatment for type 2 diabetes mellitus (T2DM) based on specific patient and agent characteristics, emphasizing individualization. With new and emerging therapies within the GLP-1 receptor agonist (GLP-1RA) class and updates to the guidelines, participants will review the most recently available information and how it can be applied to clinical practice. 

Designed by a multidisciplinary committee comprised of family physicians, pharmacists and an endocrinologist, this program highlights common scenarios in which GLP-1RAs may be considered, and provides participants an opportunity to “build” and discuss a patient case.

18:00
Hot Topics in Atrial Fibrillation

Dinner symposium supported by Servier Canada Inc.

Michael Heffernan, MD PhD FRCPC FACC

If you would like to attend this symposium please email clinicalupdate@heartandstroke.ca with the subject line: Hot Topics in Atrial Fibrillation (Your Name)

Saturday December 9, 2017 

7:00

Stroke Prevention in AF: Can We Do Better?

Breakfast Symposium supported by Bristol-Myers Squibb and Pfizer Alliance 

Jeffrey Habert MD, FCFP - Chair 
Paul Dorian MD, CM, MSc
Jeff Healey MD, FHRS

Learning objectives:

Part 1: Clinical Conundrums: Personalizing the Management of AF - Real World Worsening Kidney Function

After completing this program, participants will be able to: 

  • Explain the role of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic kidney disease (CKD); 
  • Review the clinical challenges presented by patients with worsening kidney function and transitioning from NOACs to warfarin;
  • Describe the differences, advantages, and limitations among the formulae used for estimating kidney function; estimated Glomerular Filtration Rate (eGFR) and estimated Creatinine Clearance (eCrCl). 

Learning objectives:

Part 2: Should We Be Mass Screening for AF? Here’s What We Know. 

  • After completing this program, participants will be able to: 
  • Consider the benefits of AF screening in high risk populations; 
  • Describe advantages and limitations of different AF screening tools;
  • Implement appropriate strategies to prevent stroke in AF.

The advent of DOACs, as an alternative to warfarin, has revolutionized the management of stroke prevention in atrial fibrillation. As we have gained a better understanding of the management of AF, it may be time to consider the importance of screening for AF in high-risk patient populations, and of applying appropriate treatment strategies to prevent stroke in AF. 

This two-part program will encourage you to consider the benefits of AF screening, help you to identify which of your patients should be screened, and provide you with an overview of the advantages and limitations of different screening tools. It will deepen your current understanding of the role of DOACs in the management of stroke prevention and provide guidance on dealing with clinical challenges such as patients with chronic kidney disease and the impact of renal function in the choice of therapy. 

There is much more to stroke prevention in AF than meets the eye. This program will challenge your current thinking and provide new tools and knowledge to allow you to better help your patients

Please email clinicalupdate@heartandstroke.ca if you have any questions regarding the industry symposia.